The role of calcium channel blockers in the treatment of hypertension.
D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004110:Diltiazem / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology; D004311:Double-Blind Method; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000187:drug effects; D007700:Kinetics; D007741:Labetalol / Q000494:pharmacology / Q000627:therapeutic use; D009543:Nifedipine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology; D013564:Sympathetic Nervous System / Q000187:drug effects; D014700:Verapamil / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine; D007741:Labetalol